Foster & Motley Inc. Sells 160 Shares of Danaher Co. (NYSE:DHR)

Foster & Motley Inc. lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 11.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,237 shares of the conglomerate’s stock after selling 160 shares during the period. Foster & Motley Inc.’s holdings in Danaher were worth $309,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of DHR. Patrick M Sweeney & Associates Inc. raised its position in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas raised its position in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after acquiring an additional 40 shares during the last quarter. Abacus Planning Group Inc. raised its position in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after acquiring an additional 40 shares during the last quarter. ST Germain D J Co. Inc. raised its position in shares of Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock worth $719,000 after acquiring an additional 41 shares during the last quarter. Finally, Godsey & Gibb Inc. raised its position in shares of Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after acquiring an additional 42 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $266.19 on Friday. The firm has a market cap of $197.16 billion, a PE ratio of 45.12, a PEG ratio of 4.43 and a beta of 0.83. The stock’s fifty day moving average price is $261.30 and its two-hundred day moving average price is $255.73. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on DHR shares. TD Cowen raised their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group raised their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 target price on shares of Danaher in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.